Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients

European Journal of Clinical Pharmacology

Volumn 71, Issue 9, 2015, Pages 1059-1066

  Simon, Nicolas ^a,b,f   Finzi, Jonathan ^c,d,e   Cayla, Guillaume ^c,d,e   Montalescot, Gilles ^c,d,e   Collet, Jean Philippe ^c,d,e   Hulot, Jean Sébastien ^c,d,e  

^a AIX MARSEILLE UNIV   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e Sorbonne Universités   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Clopidogrel; Drug interaction; Modelling; Nonmem; Pharmacogenetic; Pharmacokinetic; Proton pump inhibitors

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; ESOMEPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTITHROMBOCYTIC AGENT; PROTON PUMP INHIBITOR; TICLOPIDINE;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG CLEARANCE; DRUG HALF LIFE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM EFFECT; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; THROMBOCYTE AGGREGATION; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; DRUG EFFECTS; DRUG INTERACTION; FEMALE; GENETICS; MIDDLE AGED;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ALLELES; CORONARY ARTERY DISEASE; CYTOCHROME P-450 CYP2C19; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OMEPRAZOLE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 84938966621     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1882-3     Document Type: Article

References (38)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494-502
2. Steinhubl SR, Berger PB, Mann 3rd JT, et al. (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19):2411-2420
3. Sabatine MS, Cannon CP, Gibson CM, et al. (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352(12):1179-1189
4. Sabatine MS, Cannon CP, Gibson CM, et al. (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294(10):1224-1232
5. Angiolillo DJ (2009) Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 103(3 Suppl):27A-34A
6. Mega JL, Close SL, Wiviott SD, et al. (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360(4):354-362
7. Shuldiner AR, O'Connell JR, Bliden KP, et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8):849-857
8. Collet JP, Hulot JS, Pena A, et al. (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660):309-317
9. Cayla G, Hulot JS, O'Connor S, et al. (2011) Clinical, angiographic, and genetic factors associated with ealy conrn ary stent thrombosis. JAMA 306(16):1765-1774
10. Collet JP, Hulot JS, Anzaha G, et al. (2011) High doses of clopidogrel to overcome genetic resistance (the CLOVIS-2 study). JACC Cardiovasc Interv 4:392-402
11. Mega JL, Hochholzer W, Frelinger 3rd AL, et al. (2011) Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306(20):2221-2228
12. Hulot JS, Bura A, Villard E, et al. (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108(7):2244-2247
13. Simon T, Verstuyft C, Mary-Krause M, et al. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360(4):363-375
14. Kazui M, Nishiya Y, Ishizuka T, et al. (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38(1):92-99
15. Hagihara K, Kazui M, Kurihara A, et al. (2009) A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 37(11):2145-2152
16. Li XQ, Andersson TB, Ahlstrom M, Weidolf L (2004) Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32(8):821-827
17. Hulot JS, Wuerzner G, Bachelot-Loza C, et al. (2010) Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects. J Thromb Haemost 8(3):610-613
18. Cuisset T, Frere C, Quilici J, et al. (2009) Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 54(13):1149-1153
19. Gaglia MA, Jr., Torguson R, Hanna N, et al. Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes. Am J Cardiol. 2010;105(6):833-838
20. Ho PM, Maddox TM, Wang L, et al. (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301(9):937-944
21. Juurlink DN, Gomes T, Ko DT, et al. (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180(7):713-718
22. O'Donoghue ML, Braunwald E, Antman EM, et al. (2009) Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374(9694):989-997
23. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S (2009) Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 120(23):2322-2329
24. Ray WA, Murray KT, Griffin MR, et al. (2010) Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 152(6):337-345
25. Sibbing D, Morath T, Stegherr J, et al. (2009) Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101(4):714-719
26. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157(1):148 e141-148 e145
27. Small DS, Farid NA, Payne CD, et al. (2008) Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 48(4):475-484
28. Stockl KM, Le L, Zakharyan A, et al. (2010) Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 170(8):704-710
29. Yun KH, Rhee SJ, Park HY, et al. (2010) Effects of omeprazole on the antiplatelet activity of clopidogrel. Int Heart J 51(1):13-16
30. Zuern CS, Geisler T, Lutilsky N, Winter S, Schwab M, Gawaz M (2010) Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res 125(2):e51-e54
31. Hulot JS, Collet JP, Silvain J, et al. (2010) Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19∗2 loss-of-function allele or proton pump inhibitor Coadministration: a systematic meta-analysis. J Am Coll Cardiol 56:134-143
32. Angiolillo DJ, Gibson CM, Cheng S, et al. (2011) Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 89:65-74
33. Tuffal G, Roy S, Lavisse M, et al. (2011) An improved method for specific, quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost 105:696-705
34. Beal S, Sheiner L, Boeckmann AJ (eds) NONMEM user's guide. Ellicott City (MD): Icon Development Solutions,:1989-2006
35. Karlsson MO, Jonsson EN, Wiltse CG, Wade JR (1998) Assumption testing in population pharmacokinetic models: illustrated with an analysis of Moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 26:207-246
36. Brendel K, Comets E, Laffont C, Laveille C, Mentre F (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23:2036-2049
37. Navarese EP, Andreotti F, Schulze V, Kołodziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M, Parati G, Lip GY, Kelm M, Valgimigli M (2015) Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 350:h1618
38. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes Jr DR, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM (2014) DAPT study investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155-2166